Yaohai Bio-Pharma to Showcase End-to-End Microbial CRDMO Solutions at BIO International Convention 2026 in San Diego Yaohai Bio-Pharma will attend the upcoming BIO International Convention
NANJING, China, May 28, 2026 — Yaohai Bio-Pharma congratulates its strategic partner, Beijing Northland Biotechnology Co., Ltd. (“Northland Bio”), on the NMPA approval of Donaperminogene
Yaohai Bio-Pharma has once again been recognized as a leading innovator in the global biopharmaceutical industry. During the 2026 Future Healthcare 100 Conference held on
Yaohai Bio-Pharma will participate in Swiss Biotech Day 2026, one of Europe’s most influential biotechnology events. The conference will take place on May 4–5, 2026,
Yaohai Bio-Pharma today announced the launch of its end-to-end mRNA CRDMO platform, designed to support global partners across the full development lifecycle. In recent years,
On January 15, 2026, Yaohai Bio-Pharma’s strategic partner, Wuhan Huajiyuan Biotechnology Development Co., Ltd. (Huajiyuan Biotech), announced that its independently developed product, HJY-ATRQβ-001, the world’s
Biologics development faces growing challenges. These include high R&D costs, complex technologies, and long clinical timelines. Companies must balance limited resources with tight schedules. At
Yaohai Bio-Pharma is a leading CRDMO specializing in microbial expression systems. We offer end-to-end purification process development, starting from primary purification and moving all the
Yaohai Bio-Pharma provides integrated, end-to-end microbial fermentation services under the highest global GMP standards. With this combination of technology and experience, we become a reliable
Yaohai Bio-Pharma operates a cutting-edge microbial CRDMO platform built on E. coli and yeast expression systems. In addition, we offer one-stop microbial cell banking solutions
